本文已被：浏览 1673次 下载 7次
中文摘要: 目的 探究服用抗精神药物与引起精神患者代谢综合征以及认知功能的关系。方法 选取2015年6月—2017年6月来我院进行治疗的精神分裂症患者80例，并按照患者的择药意见将其分为奥氮平组、喹硫平组和阿立哌唑组，分别给予患者奥氮平、喹硫平以及阿立哌唑进行治疗。在治疗4、8和12周末从阳性和阴性症状量表(Positive and negative symptoms scale，PANSS)评分和社会功能缺陷量表(Social function defect scale，SDSS)评分方面对患者认知功能做出分析，并比较其治疗效果；在治疗4、8和12周末分别检查记录患者的体重、血糖、血脂和血压，分析研究代谢综合征的发生情况。结果 三组患者在治疗后PANSS总分、阳性症状评分、阴性症状评分以及一般病理症状评分方面均具有显著的改善，治疗前后相比具有显著差异，差异具有统计学意义(P＜0.05)。三组患者在治疗后SDSS较治疗前均有明显的减少，与治疗前比较，差异具有统计学意义(P＜0.05)；从三组患者治疗效果的结果中可以看出，在经过三种药物治疗之后，患者均具有较大的改善，其中奥氮平组的总有效率达92.59%，喹硫平组总有效率达96.30%，阿立哌唑组的总有效率达96.15%，三组相比没有显著差异。从三组患者的代谢综合征发病情况来看，奥氮平组具有较高的发病率，患病率37.03%。喹硫平组代谢综合征的患病率相对较低，患病率18.52%。阿立哌唑组患者发生代谢综合征的情况较好，仅有11.54%的发生率，与奥氮平组相比，具有显著的差异，差异具有统计学意义(P＜0.05)。结论 奥氮平、喹硫平及阿立哌唑对精神患者均具有较好的治疗效果，均能够有效的改善患者的社会认知功能；喹硫平及阿立哌唑在具有较好治疗效果的同时对患者的不良影响较小，具有较低的代谢综合征发病率，值得推广使用。
Abstract:OBJECTIVE To investigate the relationship of taking antipsychotic drugs and metabolic mental syndrome and cognitive function.METHODS 80 cases schizophrenic patients from June 2015 to June 2017 in our hospital were studied, and in accordance with the patient's views they were divided into selective drug olanzapine, quetiapine and aripiprazole group, patients were given olanzapine, quetiapine and Arab Morpheridine azole treatment. 8 and 12 weekends in the treatment of positive and negative syndrome scale(PANSS) score and Social Disability Scale (SDSS) scores in terms of cognitive function in patients made analysis, and to compared the treatment effect; 4,8,12 weekend in treatment were examined records the patient's weight, blood sugar, blood lipids and blood pressure, analysis of the incidence of metabolic syndrome.RESULTS Three groups of patients in PANSS total score, positive symptom scores, negative symptom score as well as general aspects of pathology symptom scores after treatment were significantly improved, had a significant difference, the difference was statistically significant(P＜0.05). Significantly reduced the three groups of patients before treatment after treatment compared with SDSS, compared with before treatment, the difference was statistically
significant(P＜0.05); the results from the three groups of patients with the therapeutic effect could be seen,.After treatment, patients had greatly improved, which total olanzapine effective rate 92.59%, quetiapine group, the total effective rate of 96.30%, total aripiprazole group effective rate of 96.15%, the three groups no significant difference. From the three groups of patients with metabolic syndrome incidence, the olanzapine group which had a high incidence, the total prevalence rate of 37.03%, but the prevalence of the metabolic syndrome quetiapine was relatively low its prevalence was 18.52%, the situation aripiprazole group of patients with metabolic syndrome better, only 11.54 percent rate, compared with the olanzapine group, a significant difference, the difference was statistically significant(P＜0.05).CONCLUSION Olanzapine, quetiapine and aripiprazole more mental patients have a better therapeutic effect, are able to effectively improve social cognitive function; quetiapine and aripiprazole in the treatment has a better At the same effect has little effect on patients with a lower incidence of metabolic syndrome, should be introduced.
文章编号：3201804037 中图分类号：R971 文献标志码：
基金项目:
| 作者 | 单位 |
| 李惠萍①，朱雪梅① |
| Author Name | Affiliation |
引用文本：